FunPep Company Limited (4881) AI Stock Analysis

• Market Cap: ¥4.30B
• Dividend Yield: N/A
• Average Volume (3M): 652.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 1056.04%
• EPS Growth: 21.63%
• Country: JP
• Employees: 15
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -18.24
• Shares Outstanding: 40,563,800
• 10 Day Avg. Volume: 446,760
• 30 Day Avg. Volume: 652,980
• PEG Ratio: -0.05
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

FunPep Company Limited receives a low overall stock score due to substantial financial challenges, including negative profitability and cash flow. Technical indicators reflect bearish momentum, while valuation metrics are unfavorable due to persistent losses. The lack of debt offers some stability, but the company faces significant hurdles in improving its financial health.

FunPep Company Limited Business Overview & Revenue Model

Company Description

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.

How the Company Makes Money

FunPep Company Limited generates revenue primarily through the development and commercialization of its peptide-based drugs. The company earns income by licensing its proprietary technologies and products to pharmaceutical companies and healthcare organizations. Additionally, FunPep may benefit from research and development collaborations, where it partners with other entities to co-develop treatments and shares in the resultant profits. The company's earnings are also bolstered by potential government grants or funding for research initiatives, as well as milestone payments and royalties from successfully commercialized drugs.

FunPep Company Limited Financial Statement Overview

Summary

FunPep Company Limited faces significant financial challenges, primarily due to negative profitability and cash flow metrics. The company's strong equity position and lack of debt provide some financial stability, but the inability to generate positive revenue and cash flows presents a major concern. The company needs to address operational inefficiencies and improve revenue generation to enhance financial health.

Income Statement

FunPep Company Limited has shown inconsistent revenue generation over the years, with a significant decline in revenue in recent periods. The company reported a sharp drop in revenue from 2019 to 2024, and the net income remains negative, indicating sustained losses. Both the EBIT and EBITDA margins are negative, highlighting ongoing operational challenges and inefficiencies.

Balance Sheet

The company maintains a strong equity base with no debt, resulting in a very low debt-to-equity ratio. However, the return on equity is negative due to persistent net losses, which impacts overall equity performance. The equity ratio remains healthy, indicating a strong asset base relative to liabilities.

Cash Flow

Operating cash flows are consistently negative, pointing to challenges in generating cash from core operations. Free cash flow remains negative, compounded by the absence of capital expenditure. The high operating cash flow to net income ratio indicates cash flow issues that align with reported net losses. However, the company has strong cash reserves, which provides some liquidity cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.13M	530.00K	1.07M	126.87M	2.97M
Gross Profit	-535.58M	-680.29M	-911.29M	-535.63M	-362.01M
EBITDA	-859.23M	-952.00M	-1.16B	-745.04M	-563.52M
Net Income	-889.09M	-933.42M	-1.17B	-682.26M	-507.93M
Balance Sheet
Total Assets	3.11B	2.49B	2.99B	3.36B	3.72B
Cash, Cash Equivalents and Short-Term Investments	2.35B	1.79B	2.25B	3.01B	3.62B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	563.18M	189.32M	298.11M	188.67M	152.09M
Stockholders Equity	2.55B	2.30B	2.69B	3.18B	3.57B
Cash Flow
Free Cash Flow	-537.60M	-989.87M	-1.07B	-892.79M	-413.95M
Operating Cash Flow	-536.74M	-988.82M	-1.05B	-887.47M	-413.95M
Investing Cash Flow	-30.83M	-1.05M	-19.14M	-4.75M	0.00
Financing Cash Flow	1.12B	537.81M	245.13M	282.68M	3.14B

FunPep Company Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 109.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4881, the sentiment is Neutral. The current price of 109 is below the 20-day moving average (MA) of 112.60, above the 50-day MA of 108.46, and below the 200-day MA of 125.81, indicating a neutral trend. The MACD of -1.30 indicates Positive momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 25.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4881.

FunPep Company Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	65 Neutral	¥4.65B	18.36		―	18.71%	33.40%
4594	59 Neutral	¥8.35B	―		―	1473.61%	22.80%
Sector *	57 Neutral	7.56B	6.13	-28.19%	5.55%	26.41%	6.62%
4884	54 Neutral	¥5.85B	―		―	12.66%	24.73%
2385	43 Neutral	¥4.21B	―		3.10%	-25.31%	-61.72%
4881	38 Underperform	¥4.30B	―		―	1056.04%	21.63%
4591	37 Underperform	¥5.09B	―		―	-96.64%	8.92%